In the era of SMA therapy, a deep understanding of the molecular mechanisms underlying this severe pathology is crucial to provide more clinical benefits; furthermore, we focused on the intriguing relationship between SMN and PM networks. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.